Analysts Set Immunic, Inc. (NASDAQ:IMUX) Target Price at $47.57

Shares of Immunic, Inc. (NASDAQ:IMUX) have been given an average recommendation of “Buy” by the eleven research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $47.5714.

A number of research firms have commented on IMUX. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective (up from $5.00) on shares of Immunic in a research note on Thursday, April 30th. Roth Capital restated a “buy” rating and issued a $19.00 target price on shares of Immunic in a research note on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a report on Friday, May 29th. Lifesci Capital upgraded shares of Immunic to a “strong-buy” rating in a research report on Monday, May 4th. Finally, Wolfe Research assumed coverage on shares of Immunic in a research report on Friday, May 22nd. They set an “outperform” rating on the stock.

Immunic Price Performance

Shares of IMUX opened at $13.97 on Friday. The company has a market capitalization of $190.27 million, a P/E ratio of -2.50 and a beta of 1.37. Immunic has a one year low of $5.06 and a one year high of $15.84. The business’s 50 day simple moving average is $14.29 and its 200-day simple moving average is $11.47.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.37). On average, sell-side analysts anticipate that Immunic will post -4.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Immunic

Institutional investors have recently modified their holdings of the stock. CTC Alternative Strategies Ltd. bought a new stake in shares of Immunic during the first quarter valued at approximately $27,000. Qube Research & Technologies Ltd bought a new position in Immunic in the 3rd quarter worth approximately $29,000. ADAR1 Capital Management LLC bought a new position in Immunic in the 1st quarter worth approximately $33,000. Two Sigma Investments LP acquired a new position in Immunic during the 3rd quarter worth $52,000. Finally, Seven Fleet Capital Management LP acquired a new position in Immunic during the 4th quarter worth $83,000. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.